The value of myocardial perfusion scintigraphy in the diagnosis and management of angina and myocardial infarction: a probabilistic economic analysis.
OBJECTIVE
Coronary heart disease (CHD) is the most common cause of death in the United Kingdom, accounting for more than 120,000 deaths in 2001, among the highest rates in the world. This study reports an economic evaluation of single photon emission computed tomography myocardial perfusion scintigraphy (SPECT) for the diagnosis and management of coronary artery disease (CAD).


METHODS
Strategies involving SPECT with and without stress electrocardiography (ECG) and coronary angiography (CA) were compared to diagnostic strategies not involving SPECT. The diagnosis decision was modeled with a decision tree model and long-term costs and consequences using a Markov model. Data to populate the models were obtained from a series of systematic reviews. Unlike earlier evaluations, a probabilistic analysis was included to assess the statistical imprecision of the results. The results are presented in terms of incremental cost per quality-adjusted life year (QALY).


RESULTS
At prevalence levels of CAD of 10.5%, SPECT-based strategies are cost-effective; ECG-CA is highly unlikely to be optimal. At a ceiling ratio of Pound 20,000 per QALY, SPECT-CA has a 90% likelihood of being optimal. Beyond this threshold, this strategy becomes less likely to be cost-effective. At more than Pound 75,000 per QALY, coronary angiography is most likely to be optimal. For higher levels of prevalence (around 50%) and more than a Pound 10,000 per QALY threshold, coronary angiography is the optimal decision.


CONCLUSIONS
SPECT-based strategies are likely to be cost-effective when risk of CAD is modest (10.5%). Sensitivity analyses show these strategies dominated non-SPECT-based strategies for risk of CAD up to 4%. At higher levels of prevalence, invasive strategies may become worthwhile. Finally, sensitivity analyses show stress echocardiography as a potentially cost-effective option, and further research to assess the relative cost-effectiveness of echocardiography should also be performed.
Hernández
Rodolfo
R
Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland, UK. r.a.hernandez @abdn.ac.uk
Vale
Luke
L
D000787:Angina Pectoris / Q000000981:diagnostic imaging* / Q000191:economics; D017023:Coronary Angiography / Q000191:economics; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004452:Echocardiography / Q000191:economics; D004562:Electrocardiography / Q000191:economics; D005080:Exercise Test / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D008390:Markov Chains; D017059:Models, Econometric; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000191:economics; D019057:Quality-Adjusted Life Years; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000191:economics*